The JAK1/JAK2 inhibitor Fedratinib (TG101348) reduces the growth and phosphorylation of STAT1 and STAT3 in ABC-DLBCL cells [96]. This evidence concerns the gene STAT3 and diffuse large B-cell lymphoma.